Lantern Pharma Inc. is an artificial intelligence (AI) company. Co. is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. We show 19 historical shares outstanding datapoints in our LTRN shares outstanding history coverage, used to compute LTRN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LTRN market cap history over the course of time is important for investors
interested in comparing LTRN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LTRN versus a peer is one thing; comparing
LTRN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LTRN can fluctuate over the course of history.
With this page we aim to empower investors researching LTRN by allowing them to research the LTRN market cap history. |
Free LTRN Email Alerts:
Video: The Importance of Market Cap
